Fig. 7
From: Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
Patients with high expression of ITGAV (N = 129) had a significantly poorer survival with a mean survival of 11 months than patients with low expression of ITGAV (N = 54) with a mean survival of 21 months (a). Patients with high expression of HLA-DR (N = 22) showed a significantly better survival with a mean survival of 35 months than patients with low expression of HLA-DR (N = 170) with a mean survival of 15 months (b). Representative tissue samples are given (c). Scale bar: 50 μm